Close contact restriction periods for patients who have received iodine-131 therapy for differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Radiological Protection"
DOI: 10.1088/1361-6498/acc4d0
Abstract: Patients treated with radionuclide therapy usually require restrictions on certain activities for a period of time following treatment to optimise protection of the public and ensure the legal dose limit is not exceeded. Software may… read more here.
Keywords: restriction; spreadsheet; 131 therapy; iodine 131 ... See more keywords
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092510
Abstract: Simple Summary Differentiated thyroid carcinoma (DTC) is characterized by an excellent prognosis, with the exception of cases that develop in metastatic forms. Although I-131 has been shown to be an effective therapy in patients with… read more here.
Keywords: metastatic dtc; thw; therapy; 131 therapy ... See more keywords
Radioiodine-131 Therapy Used for Differentiated Thyroid Cancer Can Impair Titanium Dental Implants: An In Vitro Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092558
Abstract: Simple Summary The alterations on dental implants seen after therapeutic radioiodine-131 exposure have important clinical impact. Several microstructural alterations start to appear at 24 h up to 2 weeks after exposure; this affects the pores… read more here.
Keywords: radioiodine 131; titanium implants; 131 therapy; dental implants ... See more keywords
Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12123154
Abstract: Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is associated with frequent toxicities… read more here.
Keywords: refractory; lenvatinib; therapy; 131 therapy ... See more keywords